36.70p+1.70 (+4.86%)04 Mar 2024, 15:50
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Sareum Holdings PLC Fundamentals

Company NameSareum Holdings PLCLast Updated2024-03-04
IndustryBiotechnologySectorHealthcare
Shares in Issue70.262 mMarket Cap£25.79 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.05EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.7520Cash Equity Ratio0.8621
Quick Ratio1.2399Current Ratio2.28
Price To Book Value21.3220ROCE0

Sareum Holdings PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Sareum Holdings PLC Company Financials

Assets202320222021
Tangible Assets£1,000.00£2,000.00£1,000.00
Intangible Assets000
Investments£46,000.00£23,000.00£26,000.00
Total Fixed Assets£47,000.00£25,000.00£27,000.00
Stocks000
Debtors£81,000.00£45,000.00£130,000.00
Cash & Equivalents£994,000.00£4.26 m£2.69 m
Other Assets000
Total Assets£2.02 m£4.79 m£3.08 m
Liabilities202320222021
Creditors within 1 year£867,000.00£455,000.00£284,000.00
Creditors after 1 year000
Other Liabilities000
Total Liabilities£867,000.00£455,000.00£284,000.00
Net assets£1.15 m£4.33 m£2.79 m
Equity202320222021
Called up share capital£851,000.00£851,000.00£833,000.00
Share Premium£20.93 m£20.93 m£17.23 m
Profit / Loss-£4.03 m-£2.58 m-£1.72 m
Other Equity£1.15 m£4.33 m£2.79 m
Preference & Minorities000
Total Capital Employed£1.15 m£4.33 m£2.79 m
Ratios202320222021
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.75201.75201.7520
Cash / Equity0.86210.86210.8621
EPS-£0.05-£0.03-£0.02
Cash Flow202320222021
Cash from operating activities-£3.27 m-£2.13 m-£1.57 m
Cashflow before financing-£3.27 m£1.58 m£921,000.00
Increase in Cash-£3.27 m£1.57 m£883,000.00
Income202320222021
Turnover000
Cost of sales000
Gross Profit000
Operating Profit-£4.07 m-£2.58 m-£1.72 m
Pre-Tax profit-£4.03 m-£2.58 m-£1.72 m

Sareum Holdings PLC Company Background

SectorHealthcare
ActivitiesSareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Latest Interim Date22 Mar 2024
Latest Fiscal Year End Date9 Oct 2023

Sareum Holdings PLC Directors

AppointedNamePosition
2023-11-08Dr. Timothy John MitchellExecutive Director,Chief Executive Officer
2023-11-08Dr. John Charles ReaderExecutive Director,Chief Scientific Officer
2016-03-14Dr. Paul Bernard HarperNon-Executive Director,Chairman
2007-11-19Dr. Alastair James RiddellNon-Executive Director
2006-06-30Mr. Edward Morgan Oliver FCAExecutive Director,Finance Director
2007-06-30Dr. David Hugh Williams, B.Sc. ,PhDExecutive Director,VP of Biology and Structural Sciences
2006-06-30Dr. Alan Gordon Lamont, PhDNon-Executive Director
2007-10-26Mr. Ernesto Giorgio Reggiani MBA,ACMA,BCommExecutive Director,Finance Director and Company Secretary
2023-11-21Dr. Stephen Barry ParkerNon-Executive Director,Chairman
2023-11-21Dr. Michael John OwenNon-Executive Director
2023-11-21Mr. Clive BirchNon-Executive Director,Company Secretary and Senior Independent Director

Sareum Holdings PLC Contact Details

Company NameSareum Holdings PLC
AddressLangford Arch, London Road, Unit 2A, Pampisford, Cambridge, CB22 3FX
Telephone+44 1223497700
Websitehttp://www.sareum.com

Sareum Holdings PLC Advisors

Nominated AdviserWH Ireland Limited
Phone+44 2072201666
Fax+44 2072201667
StockbrokerWH Ireland Ltd
Phone+44 2072201666
Fax+44 2072201667
AuditorShipleys LLP
Phone+44 2073120000
Fax+44 2073120022
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
StockbrokerHybridan LLP
Phone+44 203764 2341
Fax+44 2076001586
Financial PR AdviserCommunications Portfolio (The)
SolicitorTaylor Vinters
Phone+44 1223423444
Fax+44 1223423486